Asset
Amoxicillin
Phathom Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04167670 | phase3 | completed | 2019-12-10 | 2021-03-10 | Phathom Pharmaceuticals, Inc. | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 215152 | NDA | PHATHOM PHARMACEUTICALS INC |
| NDA 215153 | NDA | PHATHOM PHARMACEUTICALS INC |
Marketed products (2)
- VOQUEZNA DUAL PAK
- VOQUEZNA TRIPLE PAK